http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0200164-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e488341cd57d4500b986ed6b51cdf096 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4525 |
| filingDate | 2001-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2002-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0200164-A2 |
| titleOfInvention | Chemosensitizer |
| abstract | Chemotherapeutic agents are used to treat infections caused by bacteria, virus, protozoa, parasites, and various malignant diseases like cancer. The major problem associated with use of chemotherapeutic agents is resistance to chemoptherapeutic agents. The drugs restoring sensitivity of chemotherapeutic agents are broadly known as chemosensitizers. Compounds belonging to a group of R-1-3-benzodiaxole are found to be chemosensitizer as per the present invention. Piperine is one such compound belonging to R-1-2benzodiaxole group. It is found to reverse resistance to chemotherapeutic agents like rifampicin at a dose which is easily achievable after oral ingestion of the drug. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006514972-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8440625-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2468868-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006103527-A1 |
| priorityDate | 2000-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 267.